Navigation Links
MiMedx Announces Record Second Quarter Results
Date:7/31/2013

Fix® technology. In the quarter, 54% of MiMedx sales volume was for Wound Care, 41% for Surgical and Sports Medicine and 5% for "Other."

Outlook for Third Quarter and Full Year 2013
The Company reaffirmed its previously communicated guidance for full year 2013, but increased the lower end of the range. 2013 full year revenue is forecasted to be in the range of $54 million to $60 million. The Company's goals for the third quarter of 2013 are for revenue to be in the range of $13.5 million to $16.0 million. The point within the range of revenue goals largely will be dependent on whether and how quickly the remaining MACs begin to reimburse for the Company's EpiFix® allografts.

Earnings Call
MiMedx management will host a live broadcast of its second quarter results conference call on Wednesday, July 31, 2013, beginning at 10:30 a.m. eastern time.  A listen-only simulcast of the MiMedx Group conference call will be available online at the Company's website at www.mimedx.com or at www.earnings.com.  A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast.  The replay can also be found on the Company's website at www.mimedx.com or at www.earnings.com.

About the Company
MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix™, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies are processed from human a
'/>"/>

SOURCE MiMedx Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
2. MiMedx To Exceed High End Of Second Quarter Guidance
3. MiMedx to Ring NASDAQ Stock Market Opening Bell
4. MiMedx to Present at Jefferies 2013 Global Healthcare Conference
5. MiMedx Secures a $3.0 Million Revolving Line of Credit with Bank of America
6. MiMedx Announces Record First Quarter 2013 Results
7. MiMedx Group, Inc. Announces Listing on the NASDAQ Capital Market
8. MiMedx Group, Inc. Announces Release Date for 2013 First Quarter Results
9. MiMedx Responds To Inquiries Regarding Trading Activity; Reiterates First Quarter And Full Year Goals
10. MiMedx to Present at the Canaccord Genuity Musculoskeletal Conference
11. MiMedx Is Issued Four Additional U.S. Patents For Placental Tissue Grafts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Vermillion, Inc. ... on gynecologic disease, announced today that investors including ... Birchview Fund LLC and several Vermillion directors have ... shares of Vermillion,s common stock and warrants to ... a private placement.  Under the ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 The ... global leader of technical training across the life sciences ... Data Management (SCDM) to provide the organization's members ... programs —providing access to the more than 350 sessions ... members with 10% off when registering for a ...
(Date:12/22/2014)... 22, 2014  ( www.competitivehealth.com ) — Competitive Health ... bill review and advocacy service, has signed an agreement ... Savings discount health services marketplace. 63% of ... than they expected to pay. As part of an ... WellCard Savings is pleased to offer medical bill review ...
(Date:12/19/2014)... Lawrence, MA (PRWEB) December 19, 2014 ... flow MRLAFMQ test for the Detection of Aflatoxin M1 ... test to receive independent third party validation. The peer ... Science Unit of the Institute for Agricultural and Fisheries ... Francis Group. , Aflatoxin B1, the most toxic ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2
... Researchers at Rensselaer Polytechnic Institute have demonstrated ... and stability when exposed to electric fields. The ... camera lenses, cell phone displays, and other microscale ... a new vista for using nanofluids in microscale ...
... Brinks Hofer Gilson & Lione, one of,the largest intellectual ... announce that Meredith Martin Addy has been named one ... areas by Law & Politics,magazine., Intellectual property law, ... in fourteen years of practice, Ms. Addy is,among the ...
... Inc. (Nasdaq: HGSI ) today announced that it ... for the year ended,December 31, 2007. These results are ... the capital markets close., (Logo: http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO ... senior management and will be,held on Monday, February 25, ...
Cached Biology Technology:Strengthening fluids with nanoparticles 2Meredith Martin Addy Named One of Top 10 Illinois 'Super Lawyers' for 2008 2Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2007 Financial Results 2
(Date:12/17/2014)... 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend upcoming ... medical sensors in biomedical applications. Chemical sensors help ... correct diagnosis during surgical procedures. The Global Chemical ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the ... 2015-2019" report to their offering. ... is the adoption of multimodal biometric systems. Multimodal ... an individual for verification and identification purposes. This ...
(Date:12/10/2014)... Dec. 9, 2014  Valencell, a leader in performance ... a staggering demand from its licensees for highly accurate, ... is not solely coming from fitness and health sectors, ... "A wearable is only as useful as the ... the ultimate driver in long-term mass consumer adoption of ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... Lab has published recent findings that reveal some of the factors ... The paper, Stem Cell Aging is Controlled both Intrinsically ... 11 issue of Cell Stem Cell. Lei Pan, Predoctoral Researcher, and ... authors, respectively. It is ...
... base operations have left the U.S. Department of Defense (DOD) ... with highly toxic substances. University of Tennessee Research Professor ... awarded $1.3 million over three years to find the best ... keeping costs to a minimum. Parker is ...
... by Kevin Pope of Geo Eco Arc Research and ... the migration of anatomically modern humans out of Africa ... (BP). The comprehensive review of human genetic, ... the hypothesis, originally based largely on genetic evidence, that ...
Cached Biology News:Stowers Institute's Xie Lab demonstrates dual intrinsic and extrinsic control of stem cell aging 2UT researcher earns $1.3M grant to study toxic cleanup at DOD sites 2UT researcher earns $1.3M grant to study toxic cleanup at DOD sites 3Environmental setting of human migrations in the circum-Pacific Region 2
Goat polyclonal to Sarcosine Oxidase (HRP) ( Abpromise for all tested applications). Antigen: Full length protein: Sarcosine Oxidase (microbial). Entrez Gene ID: 51268 Swiss Protein ID: ...
Rabbit monoclonal [E227] to ZAP70 (phospho Y319) ( Abpromise for all tested applications). Antigen: Synthetic phospho peptide corresponding to residues surrounding Tyr319 of human ZAP70 Entre...
...
Mouse monoclonal [CIa] to Ia Antigen (Biotin) ( Abpromise for all tested applications)....
Biology Products: